XHKG
2161
Market cap263mUSD
May 30, Last price
2.55HKD
1D
0.39%
1Q
37.10%
IPO
-10.53%
Name
JBM (Healthcare) Ltd
Chart & Performance
P/E
15.86
P/S
3.19
EPS
0.16
Div Yield, %
1.59%
Shrs. gr., 5y
-0.22%
Rev. gr., 5y
16.09%
Revenues
648m
+24.62%
Net income
130m
+128.51%
CFO
191m
+31.07%
Dividend
Aug 15, 20240.0405 HKD/sh
Profile
JBM (Healthcare) Limited, an investment holding company, develops, manufactures, markets, distributes, and sells healthcare and wellness products in Asia. The company offers consumer healthcare and proprietary Chinese medicines, such as over-the-counter medicines, and medicated and non-medicated solutions, as well as diagnostic devices; and pharmaceutical products. It is also involved in the trading, wholesaling, and retailing of Chinese medicines; trading of medical supplies and pharmaceutical products; and sale of healthcare and herbal products. The company was incorporated in 2020 and is headquartered in Kwun Tong, Hong Kong. JBM (Healthcare) Limited is a subsidiary of JBM Group (BVI) Limited.
Valuation
Title HKD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | 2019‑03 | 2018‑03 | |
| Income | |||||||
Revenues | 648,415 24.62% | 520,323 28.11% | |||||
Cost of revenue | 490,546 | 470,141 | |||||
Unusual Expense (Income) | |||||||
NOPBT | 157,869 | 50,182 | |||||
NOPBT Margin | 24.35% | 9.64% | |||||
Operating Taxes | 27,680 | 13,570 | |||||
Tax Rate | 17.53% | 27.04% | |||||
NOPAT | 130,189 | 36,612 | |||||
Net income | 130,463 128.51% | 57,093 131.90% | |||||
Dividends | (52,713) | (4,468) | |||||
Dividend yield | 6.28% | 0.46% | |||||
Proceeds from repurchase of equity | (95,358) | (10,696) | |||||
BB yield | 11.36% | 1.11% | |||||
| Debt | |||||||
Debt current | 82,508 | 102,824 | |||||
Long-term debt | 69,306 | 77,273 | |||||
Deferred revenue | 77,273 | ||||||
Other long-term liabilities | (63,800) | ||||||
Net debt | (2,875) | (6,000) | |||||
| Cash flow | |||||||
Cash from operating activities | 191,216 | 145,888 | |||||
CAPEX | (10,214) | (8,133) | |||||
Cash from investing activities | 8,310 | (7,055) | |||||
Cash from financing activities | (210,723) | (56,036) | |||||
FCF | 123,517 | 114,853 | |||||
| Balance | |||||||
Cash | 140,806 | 152,266 | |||||
Long term investments | 13,883 | 33,831 | |||||
Excess cash | 122,268 | 160,081 | |||||
Stockholders' equity | 390,863 | 313,737 | |||||
Invested Capital | 1,033,083 | 1,041,625 | |||||
ROIC | 12.55% | 3.45% | |||||
ROCE | 12.63% | 3.85% | |||||
| EV | |||||||
Common stock shares outstanding | 883,696 | 891,359 | |||||
Price | 0.95 -12.04% | 1.08 18.68% | |||||
Market cap | 839,511 -12.79% | 962,668 18.37% | |||||
EV | 887,904 | 1,002,149 | |||||
EBITDA | 204,390 | 93,814 | |||||
EV/EBITDA | 4.34 | 10.68 | |||||
Interest | 8,498 | 8,209 | |||||
Interest/NOPBT | 5.38% | 16.36% | |||||